Hélène LeBlanc at the Industry, Science and Technology Committee

I am going to share my time with Mr. Harris.

Ms. Nolet and Mr. Hamill, earlier we talked about a tax credit reduction—with the rate dropping from 20% to 15%—and changes to eligible capital expenditures.

What impact will that new measure, which is included in the omnibus budget bill, have on Canada's pharmaceutical industry? I'm talking about the SR&ED program.